Why should a patient with gestational diabetes take metformin during pregnancy?

Metformin in Gestational Diabetes: Current Evidence and Recommendations

Insulin remains the preferred first-line pharmacologic treatment for gestational diabetes, with metformin reserved as a second-line option when insulin is not feasible or acceptable to the patient. This recommendation is based on the most recent 2025 Endocrine Society/European Society of Endocrinology joint guideline 1 and 2023 American Diabetes Association standards 2.

Why This Matters: The Core Issue

The question implies metformin is "important" for gestational diabetes patients to take, but current high-quality guidelines actually recommend against routine metformin use as first-line therapy 2. Here's the nuanced reality:

What Metformin Can Do (Potential Benefits)

When compared to insulin in gestational diabetes, metformin offers:

• Lower rates of neonatal hypoglycemia 3
• Reduced maternal weight gain during pregnancy 4, 5
• Decreased risk of large-for-gestational-age infants in some studies 1
• Easier administration (oral vs. injections), improving patient acceptability 6
• Lower cost and no risk of maternal hypoglycemia 1

The Critical Concerns (Why It's Not First-Line)

Metformin crosses the placenta freely, achieving fetal blood levels equal to or higher than maternal levels 3, 4, 5. This creates several problems:

1. Long-term offspring effects: The MiG TOFU study found that 9-year-old children exposed to metformin had higher BMI, increased waist-to-height ratios, and greater waist circumference compared to insulin-exposed children 4, 5. Similar findings emerged in polycystic ovary syndrome studies showing increased childhood obesity at 4-10 years 4.

2. Treatment failure rates: Nearly 25-46% of women with gestational diabetes on metformin require conversion to insulin anyway 3, 5, meaning it often doesn't suffice as monotherapy.

3. Small-for-gestational-age risk: In women with type 2 diabetes (not gestational diabetes), metformin added to insulin doubled the rate of small-for-gestational-age infants 2, 5. The 2025 Endocrine Society guideline specifically recommends against routine addition of metformin in type 2 diabetes already on insulin 1.

4. Mechanistic concerns: Animal studies show metformin concentrates 1000-fold in fetal mitochondria, decreases fetal skeletal muscle mass, and bioaccumulates in fetal kidney and liver 1.

When Metformin May Be Appropriate

Metformin should be considered only when:

• The patient cannot or will not use insulin due to cost, language barriers, comprehension issues, or cultural factors 2
• There is no evidence of placental insufficiency, hypertension, preeclampsia, or intrauterine growth restriction 2
• The patient has normal kidney function 7
• The patient understands that long-term offspring safety data are incomplete 3, 4

Critical Contraindications

Do not use metformin if:

• Hypertension or preeclampsia present (risk of fetal growth restriction) 2
• Kidney disease present 1
• Evidence of placental insufficiency 2
• Risk factors for intrauterine growth restriction 2

The Algorithm for Treatment Selection

1. First-line: Lifestyle modification (medical nutrition therapy + exercise) 2
2. If glycemic targets not met: Insulin therapy 4, 2
3. If insulin not feasible/acceptable AND no contraindications present: Consider metformin with informed consent about placental transfer and incomplete long-term safety data 2
4. Monitor closely: 25-46% will still require insulin 3, 5

Important Distinction: Gestational vs. Type 2 Diabetes

The evidence differs by diabetes type:

• Gestational diabetes: Mixed evidence, metformin may be acceptable as alternative to insulin in selected cases 1
• Type 2 diabetes in pregnancy: The 2025 guideline explicitly recommends against routine metformin addition to insulin 1

Common Pitfalls to Avoid

1. Don't assume metformin is "safer" because it's oral - it crosses the placenta while insulin does not 4, 2
2. Don't use metformin in women with hypertension or at risk for growth restriction 2
3. Don't continue metformin from PCOS treatment beyond first trimester 2
4. Don't forget to counsel about 25-46% treatment failure rates requiring insulin conversion 3, 5

The Bottom Line

Metformin is not "important" for gestational diabetes patients to take - insulin is the preferred treatment. Metformin serves as a pragmatic second-line option when insulin cannot be used, but only in carefully selected patients without contraindications, with full disclosure about placental transfer and uncertain long-term offspring effects. The 2025 Endocrine Society guideline represents the most current evidence, showing increasing caution about routine metformin use, particularly in type 2 diabetes 1.